European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia. In clinical trials the drug, a potent dopamine D3/D2 receptor partial agonist atypical antipsychotic, significantly improved symptoms of the condition and reduced the risk of relapse by 55% when compared to the placebo.
Regulatory Affairs Associate DirectorMiddlesex, London, Hertfordshire, Buckinghamshire, Berkshire, >UK
Senior Regulatory Affairs SpecialistHertfordshire, Hampshire, Essex, Buckinghamshire, Berkshire, >UK
Regulatory Affairs Officer – Compliance (France)France, EU
Regulatory Affairs Officer Senior OfficerLondon, Hertfordshire, Hampshire, Buckinghamshire, Berkshire, >UK
Reference Number: J26115 Regulatory Affairs Associate Director Locations: Buckinghamshire Salary: £70,000 – £85,000 + Competitive Benefits package Reference Number: J26115
Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.
Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.
Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.
The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.
Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.
To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:
Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.
Contact us today to find out how we can progress your career to the next level
Eli Lilly’s experimental breast cancer drug, abemaciclib, has been granted a priority review by US regulators for two indications, and is now on track to be filed in Europe later in 2017.
Jeremy Hunt, Health Secretary, and Greg Clark, Business Secretary, have recently made a bold move to suggest that the UK will consider collaborating closely with the EU in order to navigate drug approvals post-Brexit. The pharmaceutical industry has been insistent since the referendum for clearer indication of the future of drug regulation post Brexit decision